Open Access
| Issue |
BIO Web Conf.
Volume 233, 2026
9th International Conference on Advances in Biosciences and Biotechnology: Emerging Innovations in Biomedical and Bioengineering Sciences (ICABB 2026)
|
|
|---|---|---|
| Article Number | 01007 | |
| Number of page(s) | 13 | |
| Section | Biomedical and Health Innovations | |
| DOI | https://doi.org/10.1051/bioconf/202623301007 | |
| Published online | 23 April 2026 | |
- H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71 209–249 (2021). DOI: 10.3322/caac.21660 [Google Scholar]
- S.H. Hassanpour, M. Dehghani, Review of cancer from the perspective of molecular, J. Cancer Res. Pract. 4 127–129 (2017). DOI: 10.1016/j.jcrpr.2017.07.001 [Google Scholar]
- Y.S. Sun, Z. Zhao, Z.N. Yang, et al., Risk factors and preventions of breast cancer, Int. J. Biol. Sci. 13 1387–1397 (2017). DOI: 10.7150/ijbs.21635 [Google Scholar]
- S.J. Klempner, A.P. Myers, L.C. Cantley, What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway, Cancer Discov. 3 1345–1354 (2013). DOI: 10.1158/2159-8290.CD-13-0063 [Google Scholar]
- A.P. Ghosh, C.B. Marshall, T. Coric, et al., Point mutations of the mTOR-RHEB pathway in renal cell carcinoma, Oncotarget 6 17895–17907 (2015). DOI: 10.18632/oncotarget.3765 [Google Scholar]
- R.A. Saxton, D.M. Sabatini, mTOR signaling in growth, metabolism, and disease, Cell 168 960–976 (2017). DOI: 10.1016/j.cell.2017.02.004 [Google Scholar]
- P.B. Crino, The mTOR signalling cascade: paving new roads to cure neurological disease, Nat. Rev. Neurol. 12 379–392 (2016). DOI: 10.1038/nrneurol.2016.81 [Google Scholar]
- B.C. Grabiner, V. Nardi, K. Birsoy, et al., A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity, Cancer Discov. 4 554–563 (2014). DOI: 10.1158/2159-8290.CD-13-0929 [Google Scholar]
- W. Liu, W.M. Yu, J. Zhang, et al., Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations, Leukemia 31 1415–1422 (2017). DOI: 10.1038/leu.2016.386 [Google Scholar]
- L.C. Kim, R.S. Cook, J. Chen, mTORC1 and mTORC2 in cancer and the tumor microenvironment, Oncogene 36 2191–2201 (2017). DOI: 10.1038/onc.2016.363 [Google Scholar]
- T. Tian, X. Li, J. Zhang, mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy, Int. J. Mol. Sci. 20 755 (2019). DOI: 10.3390/ijms20030755 [Google Scholar]
- S.M. Chowdhury, S.A. Talukder, A.M. Khan, et al., Antiviral peptides as promising therapeutics against SARS- CoV-2, J. Phys. Chem. B 124 9785–9792 (2020). DOI: 10.1021/acs.jpcb.0c05874 [Google Scholar]
- E. Pirogova, T. Istivan, E. Gan, I. Cosic, Advances in methods for therapeutic peptide discovery, design and development, Curr. Pharm. Biotechnol. 12 1117–1127 (2011). DOI: 10.2174/138920111796117391 [Google Scholar]
- L. Bar-Peled, D.M. Sabatini, Regulation of mTORC1 by amino acids, Trends Cell Biol. 24 400–406 (2014). DOI: 10.1016/j.tcb.2014.03.003 [Google Scholar]
- R.A. Laskowski, M.B. Swindells, LigPlot+: multiple ligand-protein interaction diagrams for drug discovery, J. Chem. Inf. Model. 51 2778–2786 (2011). DOI: 10.1021/ci200227u [Google Scholar]
- S. Kumar, G. Stecher, M. Li, C. Knyaz, K. Tamura, MEGA X: molecular evolutionary genetics analysis across computing platforms, Mol. Biol. Evol. 35 1547–1549 (2018). DOI: 10.1093/molbev/msy096 [Google Scholar]
- E.F. Pettersen, T.D. Goddard, C.C. Huang, et al., UCSF Chimera—a visualization system for exploratory research and analysis, J. Comput. Chem. 25 1605–1612 (2004). DOI: 10.1002/jcc.20084 [Google Scholar]
- C. Charlier, G. Bouvignies, P. Pelupessy, et al., Structure and dynamics of an intrinsically disordered protein region that partially folds upon binding by chemical-exchange NMR, J. Am. Chem. Soc. 139 12219–12227 (2017). DOI: 10.1021/jacs.7b04153 [Google Scholar]
- P. Vanhee, E. Verschueren, L. Baeten, et al., BriX: a database of protein building blocks for structural analysis, modeling and design, Nucleic Acids Res. 39 D435–D442 (2011). DOI: 10.1093/nar/gkq1117 [Google Scholar]
- M. Petukhov, D. Cregut, C.M. Soares, L. Serrano, Local water bridges and protein conformational stability, Protein Sci. 8 1982–1989 (1999). DOI: 10.1110/ps.8.10.1982 [Google Scholar]
- V. Munoz, L. Serrano, Intrinsic secondary structure propensities of the amino acids, using statistical φ-ψ matrices: comparison with experimental scales, Proteins 20 301–311 (1994). DOI: 10.1002/prot.340200403 [Google Scholar]
- R. Abagyan, M. Totrov, Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins, J. Mol. Biol. 235 983–1002 (1994). DOI: 10.1006/jmbi.1994.1052 [Google Scholar]
- M. Vijayakumar, K.Y. Wong, G. Schreiber, A.R. Fersht, et al., Electrostatic enhancement of diffusion-controlled protein-protein association: comparison of theory and experiment on barnase and barstar, J. Mol. Biol. 278 10151024 (1998). DOI: 10.1006/jmbi.1998.1708 [Google Scholar]
- J.W. Schymkowitz, F. Rousseau, I.C. Martins, et al., Prediction of water and metal binding sites and their affinities by using the Fold-X force field, Proc. Natl. Acad. Sci. USA 102 10147–10152 (2005). DOI: 10.1073/pnas.0501980102 [Google Scholar]
- L. Baeten, J. Reumers, V. Tur, et al., Reconstruction of protein backbones from the BriX collection of canonical protein fragments, PLoS Comput. Biol. 4 e1000083 (2008). DOI: 10.1371/journal.pcbi.1000083 [Google Scholar]
- S.J. Mahoney, S. Narayan, L. Molz, et al., A small molecule inhibitor of Rheb selectively targets mTORC1 signaling, Nat. Commun. 9 1–12 (2018). DOI: 10.1038/s41467-017-02780-7 [Google Scholar]
- S. Kosugi, M. Hasebe, T. Entani, et al., Design of peptide inhibitors for the importin a/0 nuclear import pathway by activity-based profiling, Chem. Biol. 15 940–949 (2008). DOI: 10.1016/j.chembiol.2008.07.011 [Google Scholar]
- G.L. Bidwell III, D. Raucher, Therapeutic peptides for cancer therapy. Part I-peptide inhibitors of signal transduction cascades, Expert Opin. Drug Deliv. 6 1033–1047 (2009). DOI: 10.1517/17425240903143745 [Google Scholar]
- D.L. Chung, P. Brandt-Rauf, R.B. Murphy, et al., A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes, Anticancer Res. 11 1373–1378 (1991). PMID: 1718208 [Google Scholar]
- J. Haspel, D.C. Dykes, Y. Yamaizumi, et al., Inhibition of ras-oncogene-encoded p21 protein-induced maturation of oocytes by p21 peptide sequences predicted to be effector domain sites by molecular modelling, Med. Sci. Res. 20 809–811 (1992). [Google Scholar]
- D. Barnard, H. Sun, L. Baker, M.S. Marshall, In vitro inhibition of Ras-Raf association by short peptides, Biochem. Biophys. Res. Commun. 247 176–180 (1998). DOI: 10.1006/bbrc.1998.8739 [Google Scholar]
- R. Shams, Y. Ito, H. Miyatake, Development of a RHEB-targeting peptide to inhibit mTORC1 kinase activity, ACS Omega 7 17265–17276 (2022). DOI: 10.1021/acsomega.2c01744 [Google Scholar]
- H. Yang, X. Jiang, B. Li, et al., Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40, Nature 552 368–373 (2017). DOI: 10.1038/nature25023 [Google Scholar]
- C.O. Wilke, J.L. Wang, C. Ofria, et al., Evolution of digital organisms at high mutation rates leads to survival of the flattest, Nature 412 331–333 (2001). DOI: 10.1038/35085554 [Google Scholar]
- K. Fosgerau, T. Hoffmann, Peptide therapeutics: current status and future directions, Drug Discov. Today 20 122128 (2015). DOI: 10.1016/j.drudis.2014.10.003 [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.